welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

key information

study id #: NCT02485938

condition: Duchenne Muscular Dystrophy, Cardiomyopathy

status: completed


Male subjects with cardiomyopathy secondary to Duchenne muscular dystrophy (DMD) meeting all inclusion and no exclusion criteria will be randomized. All subjects will be at least 12 years of age. They will be randomized in a 1:1 manner to either intracoronary infusion of CAP-1002 in three coronary arteries supplying the three major cardiac territories of the left ventricle of the heart (anterior, lateral, inferior/posterior) or usual care. In the active treatment arm, all three major cardiac territories will be treated (infused) during a single procedure in an open-label fashion.

intervention: Allogeneic Cardiosphere-Derived Cells (CAP-1002)

mechanism of action: Cardiac progenitor cells to promote cellular regeneration

results: https://clinicaltrials.gov/ct2/show/results/NCT02485938

last updated: November 22, 2018